{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.3","value":"74.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"}],"units":"Participants"}],"description":"Maximum observed plasma concentration of ibrutinib was determined using PopPK modeling.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received ibrutinib capsules 560 mg (4\\*140 mg capsule) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end, whichever occurred first. All participants also received a maximum of 6 cycles of BR background therapy (bendamustine hydrochloride 90 mg/m\\^2 IV infusion on Days 1 and 2 of each cycle and rituximab 375 mg/m\\^2 IV infusion on Day 1 of each cycle), unless disease progression or unacceptable toxicity prior to Cycle 6. Participants with a CR or PR continued to receive background therapy with rituximab maintenance (375 mg/m\\^2 IV infusion) on Day 1 every second cycle starting at Cycle 8 for a maximum of 12 additional doses unless disease progression or unacceptable toxicity. Each cycle was of 28 days. Participants received treatment B up to 117.2 months. After treatment unblinding at the time of the primary analysis, participants randomized to Treatment B continued treatment with ibrutinib at the discretion of the investigator.","id":"OG000","title":"Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic-evaluable population included participants who have received at least 1 dose of ibrutinib/placebo and had at least 1 pharmacokinetic sample obtained posttreatment.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2","title":"Maximum Observed Plasma Concentration of Ibrutinib","type":"SECONDARY","unitOfMeasure":"ng/mL"}